Abstract
Keratinocyte Growth factor (KGF) is an epithelial cell growth factor of the fibroblast growth factor family and is produced by fibroblasts and microvascular endothelium in response to proinflammatory cytokines and steroid hormones. KGF is a heparin binding growth factor that exerts effects on epithelial cells in a paracrine fashion through interaction with KGF receptors. Preclinical data has demonstrated that KGF can prevent lung and gastrointestinal toxicity following chemotherapy and radiation and preliminary clinical data in the later setting supports these findings. In the experimental allogeneic bone marrow transplant scenario KGF has shown significant ability to prevent graft-versus-host disease by maintaining gastrointestinal tract integrity and acting as a ”cytokine shield“ to prevent subsequent proinflammatory cytokine generation. Within this setting KGF has also shown an ability to prevent experimental idiopathic pneumonia syndrome by stimulating production of surfactant protein A, promoting alveolar epithelialization and attenuating immune-mediated injury. Perhaps most unexpectantly, KGF appears able to maintain thymic function during allogeneic stem cell transplantation and so promote T cell engraftment and reconstitution. These data suggest that KGF will find a therapeutic role in the prevention of epithelial toxicity following intensive chemotherapy and radiotherapy protocols and in allogeneic stem cell transplantation.
Keywords: keratinocyte growth factor(kgf), mucositis
Current Pharmaceutical Design
Title: Keratinocyte Growth Factor (KGF) in Hematology and Oncology
Volume: 8 Issue: 5
Author(s): Kelli P.A. MacDonald and Geoffrey R. Hill
Affiliation:
Keywords: keratinocyte growth factor(kgf), mucositis
Abstract: Keratinocyte Growth factor (KGF) is an epithelial cell growth factor of the fibroblast growth factor family and is produced by fibroblasts and microvascular endothelium in response to proinflammatory cytokines and steroid hormones. KGF is a heparin binding growth factor that exerts effects on epithelial cells in a paracrine fashion through interaction with KGF receptors. Preclinical data has demonstrated that KGF can prevent lung and gastrointestinal toxicity following chemotherapy and radiation and preliminary clinical data in the later setting supports these findings. In the experimental allogeneic bone marrow transplant scenario KGF has shown significant ability to prevent graft-versus-host disease by maintaining gastrointestinal tract integrity and acting as a ”cytokine shield“ to prevent subsequent proinflammatory cytokine generation. Within this setting KGF has also shown an ability to prevent experimental idiopathic pneumonia syndrome by stimulating production of surfactant protein A, promoting alveolar epithelialization and attenuating immune-mediated injury. Perhaps most unexpectantly, KGF appears able to maintain thymic function during allogeneic stem cell transplantation and so promote T cell engraftment and reconstitution. These data suggest that KGF will find a therapeutic role in the prevention of epithelial toxicity following intensive chemotherapy and radiotherapy protocols and in allogeneic stem cell transplantation.
Export Options
About this article
Cite this article as:
MacDonald P.A. Kelli and Hill R. Geoffrey, Keratinocyte Growth Factor (KGF) in Hematology and Oncology, Current Pharmaceutical Design 2002; 8 (5) . https://dx.doi.org/10.2174/1381612023396104
DOI https://dx.doi.org/10.2174/1381612023396104 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of microRNAs in Non-Alcoholic Steatohepatitis
Current Pharmaceutical Design Life or Death? A Physiogenomic Approach to Understand Individual Variation in Responses to Hemorrhagic Shock
Current Genomics Attenuating Muscle Wasting: Cell and Gene Therapy Approaches
Current Genomics Cardiac Fat as New Diagnostic Tool and Potential Therapeutic Target for Obesity Management and Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Comparison of the Neutrophil Proteome in Trauma Patients and Normal Controls
Protein & Peptide Letters Synthesis and Cytotoxic Evaluation of Kojic Acid Derivatives with Inhibitory Activity on Melanogenesis in Human Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry microRNA in Chondrogenesis, Cartilage and Osteoarthritis
Current Rheumatology Reviews Connecting A Tumor to the Environment
Current Pharmaceutical Design Detection of Klebsiella Antibodies and HLA-B27 Allelotypes Could be Used in the Early Diagnosis of Ankylosing Spondylitis with a Potential for the Use of “Low Starch Diet” in the Treatment
Current Rheumatology Reviews The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews Novel Molecular Targets for the Prevention of Fetal Alcohol Syndrome
Recent Patents on CNS Drug Discovery (Discontinued) Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Current Cancer Therapy Reviews Hedgehog Signaling and Urological Cancers
Current Drug Targets Pharmacogenetics in Methadone Therapy
Current Pharmacogenomics and Personalized Medicine Insights on Natural Products Against Amyotrophic Lateral Sclerosis (ALS)
Current Neuropharmacology Biomarker-Detection Technologies for Comprehensive Medical Diagnosis During Deep-Space Missions
Recent Patents on Space Technology Inhibition of Interleukin-6 Dependent Metalloproteinases-9/2 Expression in Cancer Cells by Diet Polyphenols
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review
Current Neuropharmacology A Catalytically Inactive Lys49 PLA2 Isoform from Bothrops jararacussu venom that Stimulates Insulin Secretion in Pancreatic Beta Cells
Protein & Peptide Letters